Cerca de 15% a 20% das mulheres com gravidez molar completa, e 0.5% a 5% das mulheres com gravidez molar parcial desenvolvem NTG e precisam de quimioterapia.[4]Ngan HYS, Seckl MJ, Berkowitz RS, et al. Diagnosis and management of gestational trophoblastic disease: 2021 update. Int J Gynaecol Obstet. 2021 Oct;155 Suppl 1(suppl 1):86-93.
https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.13877
http://www.ncbi.nlm.nih.gov/pubmed/34669197?tool=bestpractice.com
[42]Lok C, van Trommel N, Massuger L, et al. Practical clinical guidelines of the EOTTD for treatment and referral of gestational trophoblastic disease. Eur J Cancer. 2020 May;130:228-40.
http://www.ncbi.nlm.nih.gov/pubmed/32247260?tool=bestpractice.com
No entanto, o índice de cura para essas afecções é superior a 95%.[34]Tidy, J, Seckl, M, Hancock, BW, on behalf of the Royal College of Obstetricians and Gynaecologists. Management of gestational trophoblastic disease. BJOG 2021;128: e1-e27.
https://obgyn.onlinelibrary.wiley.com/doi/full/10.1111/1471-0528.16266
Mulheres com diagnóstico prévio de mola hidatiforme têm risco de 1% a 2% (ou cerca de 10 vezes a linha basal) de gravidez molar em gestações subsequentes.[8]Sebire NJ, Fisher RA, Foskett M, et al. Risk of recurrent hydatidiform mole and subsequent pregnancy outcome following complete or partial hydatidiform molar pregnancy. BJOG. 2003 Jan;110(1):22-6.
http://www.ncbi.nlm.nih.gov/pubmed/12504931?tool=bestpractice.com
[9]Vargas R, Barroilhet LM, Esselen K, et al. Subsequent pregnancy outcomes after complete and partial molar pregnancy, recurrent molar pregnancy, and gestational trophoblastic neoplasia: an update from the New England Trophoblastic Disease Center. J Reprod Med. 2014 May-Jun;59(5-6):188-94.
http://www.ncbi.nlm.nih.gov/pubmed/24937955?tool=bestpractice.com
As mulheres devem ser acompanhadas rigorosamente em gestações subsequentes.[3]Horowitz NS, Eskander RN, Adelman MR, et al. Epidemiology, diagnosis, and treatment of gestational trophoblastic disease: A Society of Gynecologic Oncology evidenced-based review and recommendation. Gynecol Oncol. 2021 Dec;163(3):605-13.
https://www.gynecologiconcology-online.net/article/S0090-8258(21)01421-9/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/34686354?tool=bestpractice.com
(consulte Prevenção)